Aclara Q4 Revenues Slip, Net Losses Widen | GenomeWeb

NEW YORK, Feb 21 – Aclara Biosciences said Wednesday its fourth-quarter 2000 revenues slipped to $733,000, from $855,000 a year ago, as declining revenues from a drug screening offset revenue increases from government grants and a collaboration with Cellomics.

For 2000, revenues were up 21 percent to $3.5 million, mostly as a result of the Cellomics partnership.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.